MaaT Pharma: positive results in blood cancers
The Lyon-based biotech presented encouraging efficacy data at the annual conference of the American Society of Hematology (ASH), currently being held in the USA.
In 111 patients with acute graft-versus-host disease (aGvH) treated with its MaaT013, the overall gastrointestinal response rate reached 53% by day 28, with a significant impact on overall survival (OS) in responder patients.
The company points out that these results are even more pronounced for the patient population with a similar profile to those treated in the Phase 3 clinical trial, with a response rate of 61% at day 28.
In a press release, MaaT adds that its drug candidate has demonstrated a good safety profile and an increase in overall survival, reinforcing its favorable benefit-risk profile.
Listed on the Paris Bourse, the share climbed by over 10% following these announcements.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction